The stimulating action of ACTH and related polypeptides on the spontaneous rhythm of isolated heart muscle cells in vitro

1963 ◽  
Vol 56 (5) ◽  
pp. 1187-1191
Author(s):  
A. Vollenberger ◽  
V. Galle
Keyword(s):  
Heart Muscle ◽  
Isolated Heart ◽  
Muscle Cells ◽  
Heart Muscle Cells ◽  
Spontaneous Rhythm

Luminometric Measurement of Subnanomole Amounts of Key Metabolites in Extracts from Isolated Heart Muscle Cells

1996 ◽  
Vol 239 (1) ◽  
pp. 41-46 ◽  
Author(s):  
E. Jüngling ◽  
M. Timmerman ◽  
A.Aretz, I. Ionescu ◽  
M. Mertens ◽  
C. Löken ◽  
...  
Keyword(s):  
Heart Muscle ◽  
Isolated Heart ◽  
Muscle Cells ◽  
Heart Muscle Cells

Pulsatile activity of isolated heart muscle cells after freezing storage

Cryobiology ◽  
1968 ◽  
Vol 4 (4) ◽  
pp. 200-203 ◽  
Author(s):  
E. Schöpf-Ebner ◽  
W.O. Gross ◽  
O.M. Bucher
Keyword(s):  
Heart Muscle ◽  
Isolated Heart ◽  
Muscle Cells ◽  
Heart Muscle Cells ◽  
Freezing Storage

scholarly journals Modelling and Simulation for Preclinical Cardiac Safety Assessment of Drugs with Human iPSC-Derived Cardiomyocytes

2020 ◽  
Vol 122 (4) ◽  
pp. 209-257 ◽  
Author(s):  
Philipp Kügler
Keyword(s):  
Drug Safety ◽  
Heart Muscle ◽  
Cardiac Electrophysiology ◽  
Human Heart ◽  
Cardiac Activity ◽  
Muscle Cells ◽  
Estimation Methods ◽  
Proarrhythmic Risk ◽  
Heart Muscle Cells

Abstract As a potentially life threatening side effect, pharmaceutical compounds may trigger cardiac arrhythmias by impeding the heart’s electrical and mechanical function. For this reason, any new compound needs to be tested since 2005 for its proarrhythmic risk both during the preclinical and the clinical phase of the drug development process. While intensive monitoring of cardiac activity during clinical tests with human volunteers constitutes a major cost factor, preclinical in vitro tests with non cardiac cells and in vivo tests with animals are currently under serious debate because of their poor extrapolation to drug cardiotoxicity in humans. For about five years now, regulatory agencies, industry and academia are working on an overhaul of the cardiac drug safety paradigm that is built a) on human heart muscle cells, that can be abundantly bioengineered from donor stem cells without ethical concerns (human induced pluripotent stem cell derived cardiomyocytes, hiPSC-CMs), and b) on computational models of human cardiac electrophysiology both at the cellular and the organ level. The combined use of such human in vitro and human in silico models during the preclinical phase is expected to improve proarrhythmia test specificity (i.e. to lower the false-positive rate), to better inform about the need of thorough heart monitoring in the clinic, and to reduce or even replace animal experiments. This review article starts by concisely informing about the electrical activity of the human heart, about its possible impairment due to drug side effects, and about hiPSC-CM assays for cardiac drug safety testing. It then summarizes the mathematical description of human cardiac electrophysiology in terms of mechanistic ODE and PDE models, and illustrates how their numerical analysis may provide insight into the genesis of drug induced arrhythmias. Finally, this paper surveys proarrhythmic risk estimation methods, that involve the simulation of human heart muscle cells, and addresses opportunities and challenges for future interdisciplinary research.

Technique for the preparation of homogeneous cultures of isolated heart muscle cells

1968 ◽  
Vol 53 (1) ◽  
pp. 1-10 ◽  
Author(s):  
W.O. Gross ◽  
E. Schöpf-Ebner ◽  
O.M. Bucher
Keyword(s):  
Heart Muscle ◽  
Isolated Heart ◽  
Muscle Cells ◽  
Heart Muscle Cells
Sign in / Sign up

Export Citation Format

Share Document